PremiumCompany AnnouncementsJasper Therapeutics Faces Financial Challenges Amid Rising R&D Costs Jasper Therapeutics reports Q1 EPS ($1.41), consensus ($1.48) JSPR Earnings Report this Week: Is It a Buy, Ahead of Earnings? PremiumRatingsPositive Outlook on Jasper Therapeutics: Sustained Efficacy and Safety of Briquilimab in CSU Treatment Promising Outlook for Jasper Therapeutics: Buy Rating Amidst Potential Upside and Strategic Developments Jasper Therapeutics presents updated data from Phase 1b/2a BEACON study PremiumRatingsPromising Data from Jasper Therapeutics’ BEACON and SPOTLIGHT Studies Justify Buy Rating for Briquilimab Jasper Therapeutics reports Q4 EPS ($1.62), consensus ($1.23) Jasper Therapeutics initiated with a Buy at UBS 
